Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice.
- Published In:
- European journal of pharmacology, 811, 30-37 (2017)
- Database ID:
- RPEP-03537
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03537APA
Yoshimura, Makoto; Shiomi, Yoshihiro; Ohira, Yuta; Takei, Mineo; Tanaka, Takao. (2017). Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice.. European journal of pharmacology, 811, 30-37. https://doi.org/10.1016/j.ejphar.2017.05.036
MLA
Yoshimura, Makoto, et al. "Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice.." European journal of pharmacology, 2017. https://doi.org/10.1016/j.ejphar.2017.05.036
RethinkPeptides
RethinkPeptides Research Database. "Z-505 hydrochloride, an orally active ghrelin agonist, atten..." RPEP-03537. Retrieved from https://rethinkpeptides.com/research/yoshimura-2017-z505-hydrochloride-an-orally
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.